RA ℞: T-Cell Co-Stimulation Blockade

A window of opportunity for abatacept in RA: is disease duration an independent predictor of low disease activity/remission in clinical practice?

The objective of the study was to examine whether disease duration independently predicts treatment response among biologic-naïve patients with rheumatoid arthritis (RA) initiating abatacept in clinic

Abatacept may benefit ACPA-negative undifferentiated arthritis

Abatacept therapy prevented further progression of disease in 18 of 20 patients, but many patients needed additional therapy to maintain the halt in disease…